Is high-risk BCR really mHSPC?? Live webinar replay

Written By Declan Murphy

We recently hosted another live webinar for our Gold Partners, Mundipharma, this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.

Runsheet:

  • Is high-risk biochemical recurrence already metastatic prostate cancer? Declan Murphy

  • Is the management of high-risk BCR and mHSPC now the same? Jeffrey Goh

  • Prostate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew Loblaw

  • Q&A and case discussions

This webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.

 

Also available as an audio podcast - just search GU Cast wherever you get your podcasts, or play directly below

Declan Murphy
Next

SABR and LuPSMA for mHSPC? Let's talk LUNAR